MARKET

BLPH

BLPH

Bellerophon
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.67
+1.30
+11.43%
After Hours: 13.52 +0.85 +6.71% 19:56 03/27 EDT
OPEN
11.04
PREV CLOSE
11.37
HIGH
13.00
LOW
10.55
VOLUME
324.48K
TURNOVER
--
52 WEEK HIGH
26.00
52 WEEK LOW
3.186
MARKET CAP
58.03M
P/E (TTM)
-0.3730
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of BLPH and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average BLPH stock price target is 30.00 with a high estimate of 30.00 and a low estimate of 30.00.

EPS

BLPH News

More
  • HOV, ONCY, MFA and IVR among midday movers
  • Seeking Alpha - Article · 3d ago
  • Bristol Plavix Setback, And Other News: The Good, Bad And Ugly Of Biopharma
  • Seeking Alpha - Article · 4d ago
  • SVM, ADMA, AHT and MITT among midday movers
  • Seeking Alpha - Article · 4d ago
  • Company News for Mar 23, 2020
  • Zacks · 4d ago

Industry

Biotechnology & Medical Research
-2.43%
Pharmaceuticals & Medical Research
-0.87%

Hot Stocks

Symbol
Price
%Change

About BLPH

Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication. Its INOpulse device has a mechanism that delivers brief, targeted pulses of nitric oxide timed to occur at the beginning of a breath for delivery to the alveoli of the lungs, which minimizes the amount of drug required for treatment. The Company's second program, BCM, is a medical device focused to prevent congestive heart failure following a ST Segment Elevation Myocardial Infarction (STEMI), which is a type of severe heart attack. The Company's BCM is in PRESERVATION I clinical trial.
More

Webull offers kinds of Bellerophon Therapeutics Inc stock information, including NASDAQ:BLPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BLPH stock news, and many more online research tools to help you make informed decisions.